1,3-diazaazulene | 275-94-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1,3-diazaazulene
• 英文别名: 1,3-Diaza-azulen；1,3-Diazazulen；Cycloheptimidazole；cyclohepta[d]imidazole
• CAS: 275-94-5
• 化学式: C₈H₆N₂
• 分子量: 130.149
• InChiKey: HPGSSIJHLUDJFV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1,3-diazaazulene 在 potassium dichromate 、 sodium hydroxide 、 硫酸 作用下， 生成 2-苯基-1H-咪唑-4,5-二甲酸
  参考文献：
  名称：

  Benzoylation of 1,3-Diazaazulene

  摘要：

  DOI：

  10.1246/bcsj.32.841
• 作为产物：
  描述：

  1H-cycloheptaimidazole-2-thione 在 双氧水 作用下， 反应 0.5h， 以60%的产率得到1,3-diazaazulene
  参考文献：
  名称：

  yl鎓环化的N-杂环卡宾。

  摘要：

  通过氢化物从相关的环庚三烯化合物中提取氢化物，可以得到阳离子对苯二甲酰基咪唑基亚烷基ITrop +的衍生物。光谱，结构和理论数据表明，ITrop +作为苯并咪唑基亚胺的阳离子亲和性，具有高度还原的σ供体和强的π受体特性。

  DOI：

  10.1039/d0cc04482b

文献信息

• Studies on Heterocyclic Analogs of Azulene. VI. Cycloadditions of Styryl-substituted Aza Analogs of Azulene with Dimethyl Acetylenedicarboxylate
  作者：Noritaka Abe、Tarozaemon Nishiwaki

  DOI：10.1246/bcsj.53.1406

  日期：1980.5

  8-[(E)-Styryl]-1-azaazulenes stereospecifically react with dimethyl acetylenedicarboxylate to form trans-7H-6a-azacyclobuta[j]cyclopent[cd]azulene (3), which undergoes thermal rearrangement into 3-[(E)-styryl]3H-2a-azacyclopent[cd]azulene and 3a,4-dihydro-3H-2a-azadicyclopent[cd, ij]azulene (7), or isomerization into 3H-2a-azacyclopenta[ef]heptalene by silica gel. Compound 7 is oxidized during the

  8-[(E)-Styryl]-1-azaazulenes 与二甲炔二甲酸二甲酯发生立体特异性反应，形成 trans-7H-6a-azacyclobuta[j]cyclopent[cd]azulene (3)，后者经过热重排成为 3-[(E) -styryl]3H-2a-azacyclopent[cd]azulene 和 3a,4-dihydro-3H-2a-azadicyclopent[cd, ij]azulene (7)，或通过硅胶异构化成 3H-2a-azacyclopenta[ef]heptalene。化合物 7 在反应过程中被氧化，生成 11-oxo-2aH-7,10b-methano-2a-azacyclopenta[ab]cycloundecene，化合物 3 形成 5a,6-dihydro-3H-2a-azadicyclopenta[ef, kl]与乙炔反应生成庚烷。3 的形成可以用对称允许的热
• Methine dyes
  申请人：Fuji Photo Film Co., Ltd.

  公开号：US05003077A1

  公开（公告）日：1991-03-26

  Methine dye which contains a cycloheptimidazole nucleus having a substituent at its 1-position thereof and in which the 7-membered ring moiety is substituted by a methine bond having an auxochrome, at the terminal thereof, for forming a conjugated resonance chromophoric group with the 10 .pi. electron series of the nucleus, showing a long absorption with one or a few methine bonds and have high light-stability and solution-stability.

  含有环庚咪唑核并在其1-位置具有取代基的甲烷染料，其中7-成员环部分被具有辅基的甲烷键取代，用于与核心的10个.π.电子系列形成共轭共振色团，显示出具有一个或几个甲烷键的长吸收，并具有高光稳定性和溶液稳定性。
• Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of selective serotonin reuptake inhibitor (SSR) induced sexual dysfunction
  申请人：——

  公开号：US20030055070A1

  公开（公告）日：2003-03-20

  This invention is directed to the use phosphodiesterase type 5 (PDE5) inhibitors in the treatment of selective serotonin reuptake inhibitor (SSRI) induced sexual dysfunction. Specifically, this invention is directed to a method for treating an animal to cure; prevent or ameliorate SSRI induced sexual dysfunction which comprises administering to the animal an effective amount of the inhibitor. The animal may be a male or a female human. The invention also includes the use of such inhibitors in the manufacture of a medicament to prevent; cure or ameliorate SSRI induced sexual dysfunction. Moreover, the invention includes a kit comprising a SSRI, such as sertraline, fluoxetine, paroxetine, and a PDE5 inhibitor, such as sildenafil citrate, for the treatment or prevention of serotonergic associated disorders such as depression, obsessive compulsive disorder or panic disorder, while reducing or preventing sexual dysfunction.

  该发明涉及使用磷酸二酯酶-5（PDE5）抑制剂治疗选择性血清素再摄取抑制剂（SSRI）引起的性功能障碍。具体而言，该发明涉及一种治疗动物以治愈、预防或改善SSRI引起的性功能障碍的方法，包括向动物施用有效量的抑制剂。该动物可以是男性或女性人类。该发明还包括将这些抑制剂用于制造药物以预防、治愈或改善SSRI引起的性功能障碍。此外，该发明还包括一种套装，其中包括SSRI（如舍曲林、氟西汀、帕罗西汀）和PDE5抑制剂（如西地那非）用于治疗或预防血清素相关疾病，如抑郁症、强迫症或惊恐症，同时减少或预防性功能障碍。
• Methods and compositions for treating diseases and conditions of the eye
  申请人：——

  公开号：US20020119974A1

  公开（公告）日：2002-08-29

  Methods for the prevention and treatment of diseases and conditions of the eye including, but are not limited to: central retinal artery occlusion; central retinal vein occlusion; optic neuropathy including, but not limited to, anterior ischemic optic neuropathy and glaucomatous optic neuropathy; and macular (dry) degeneration are disclosed. These methods comprise administering to a patient a prophylactically or therapeutically effective amount of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase type 5 inhibitor. Pharmaceutical compositions and dosage forms comprising cyclic guanosine 3′,5′-monophosphate phosphodiesterase type 5 inhibitors are also disclosed.

  披露了预防和治疗眼部疾病和病况的方法，包括但不限于：中央视网膜动脉阻塞；中央视网膜静脉阻塞；视神经病变，包括但不限于前部缺血性视神经病变和青光眼性视神经病变；以及黄斑（干性）变性。这些方法包括向患者投予预防性或治疗性有效量的环鸟苷3′,5′-单磷酸磷酸二酯酶类型5抑制剂。还披露了含有环鸟苷3′,5′-单磷酸磷酸二酯酶类型5抑制剂的药物组合物和剂型。
• Studies on Heterocyclic Analogs of Azulene. VII. Regioselective Cycloadditions of Cycloheptimidazole to Electron-deficient Olefins
  作者：Noritaka Abe、Tarozaemon Nishiwaki

  DOI：10.1246/bcsj.53.1773

  日期：1980.6

  Cycloheptimidazole reacted with electrondeficient olefins (e.g., ethyl acrylate or acrylonitrile) to give the regioselective [6+2] cycloadducts, which were readily dehydrogenated to give 2a,3-dihydro-1,2a-diazacyclopent[cd]azulenes.

  环庚烷咪唑与缺电烯烃（如丙烯酸乙酯或丙烯腈）反应生成具有区域选择性的[6+2]环加载物，这些环加载物很容易脱氢生成 2a,3-二氢-1,2a-二氮杂环戊[cd]氮烯。

表征谱图